Semaglutide is a medication that is FDA-approved for the treatment of type 2 diabetes, but it has also been studied for its potential benefits in weight loss. In fact, semaglutide has been shown to cause significant and sustained weight loss in clinical trials.

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, which works by mimicking the natural hormone GLP-1 to help regulate appetite and metabolism. When taken once a week, semaglutide has been shown to cause a significant reduction in body weight, particularly in individuals who are obese or overweight.

The most notable clinical trial for semaglutide’s use in weight loss was the STEP-WT trial, which found that participants who took semaglutide lost an average of 14.9% of their initial body weight over 40 weeks, compared to 2.3% with placebo. Additionally, semaglutide has been shown to improve various cardiovascular risk factors, such as blood pressure and triglycerides.

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist medication used to treat type 2 diabetes. It works by mimicking the action of natural GLP-1, which helps to regulate blood sugar levels by stimulating insulin production and suppressing glucagon production. Semaglutide has been shown to improve glycemic control, reduce the risk of major adverse cardiovascular events, and promote weight loss in patients with type 2 diabetes. It is available as a once-weekly injection and is also being studied as a treatment for other conditions such as obesity and non-alcoholic steatohepatitis (NASH).